Iwata Teruo, Uramoto Hidetaka, Sugio Kenji, Fujino Yoshihisa, Oyama Tsunehiro, Nakata Shoji, Ono Kenji, Morita Masaru, Yasumoto Kosei
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Lung Cancer. 2005 Oct;50(1):67-73. doi: 10.1016/j.lungcan.2005.03.039.
DeltaNp63 is an isoform of the p53 homologue p63, which lacks an amino-terminal transactivation domain and antagonizes the induction of the gene expression by Deltap63. The aim of this study was to detect the DeltaNp63 expression in lung cancer using immunohistochemical (IHC) staining, and to evaluate the relationship between theDeltaNp63 expression level and the prognosis based on resected lung cancer tissues specimens from the of patients. We used immunohistochemistry to analyze the protein expression of DeltaNp63 in paraffin-embedded tumor samples from 161 well-characterized squamous cell carcinoma patients and compared the expression level of DeltaNp63, clinical variables and the survival outcome. Seventy-seven patients (47.8%) showed positive staining for DeltaNp63 in the nuclei of tumor cells. No significant difference was observed between the DeltaNp63 expression and the gender, age at operation, pathologic stage, pathologic T status, and pathologic N status. Based on the actuarial survival method, Kaplan-Meier method, and the log-rank test, the DeltaNp63 expression was not associated with survival for lung cancer. Differences in survival remained insignificant even after lung cancer patients were stratified according to stage or differentiation. The prognostic effects of DeltaNp63 expression do not appear to act as an important prognostic indicator in lung cancer. Our findings do not support that immunocytochemical markers demonstrate a relevant prognostic role in lung cancer.
DeltaNp63是p53同源物p63的一种异构体，它缺乏氨基末端反式激活结构域，并拮抗Delta p63对基因表达的诱导作用。本研究的目的是采用免疫组织化学（IHC）染色检测肺癌中DeltaNp63的表达，并基于患者的手术切除肺癌组织标本评估DeltaNp63表达水平与预后之间的关系。我们采用免疫组织化学方法分析了161例特征明确的鳞状细胞癌患者石蜡包埋肿瘤样本中DeltaNp63的蛋白表达，并比较了DeltaNp63的表达水平、临床变量和生存结果。77例患者（47.8%）肿瘤细胞核中DeltaNp63染色呈阳性。DeltaNp63表达与性别、手术年龄、病理分期、病理T状态和病理N状态之间未观察到显著差异。基于精算生存法、Kaplan-Meier法和对数秩检验，DeltaNp63表达与肺癌生存无关。即使根据分期或分化对肺癌患者进行分层后，生存差异仍然不显著。DeltaNp63表达的预后作用似乎并非肺癌的重要预后指标。我们的研究结果不支持免疫细胞化学标志物在肺癌中具有相关预后作用这一观点。
